Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan vs. FDA (And Ranbaxy): Diovan Exclusivity Forfeiture Edition

This article was originally published in The Pink Sheet Daily

Executive Summary

In a suit against FDA, Mylan argues that Ranbaxy’s delay in getting tentative approval for its valsartan ANDA within 30 months of submission triggered forfeiture of its 180-day marketing exclusivity.

You may also be interested in...



Ranbaxy’s Valsartan ANDA Wins FDA Approval After Lengthy Delay

Regulatory nod gives Ranbaxy green light to launch its generic version of Novartis’ Diovan with 180-day exclusivity; other ANDA holders may continue to challenge Ranbaxy’s hold on the market.

Teva Claims Diovan 180-Day Exclusivity, Arguing Ranbaxy ANDA Was Incomplete

Teva supports citizen petition claiming Ranbaxy is ineligible for exclusivity but says that it is the actual first ANDA filer; generic has yet to launch nearly two years after Novartis’ Diovan patents expired.

Teva Claims Diovan 180-Day Exclusivity, Arguing Ranbaxy ANDA Was Incomplete

Teva supports citizen petition claiming Ranbaxy is ineligible for exclusivity but says that it is the actual first ANDA filer; generic has yet to launch nearly two years after Novartis’ Diovan patents expired.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073459

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel